PainTEQ Announces US Launch of SI Joint Implant

Why It Matters

The TRAQ launch broadens minimally invasive options for SI‑joint pain, potentially increasing market share for posterior fusion technologies and generating real‑world evidence that could shape reimbursement and adoption.

Key Takeaways

• TRAQ implant launches commercially in the United States.
• Triangular barbs enable bicortical fixation of sacral and iliac cortices.
• Procedure uses 1‑inch posterior incision with pre‑filled graft window.
• TRAQTION study will enroll up to 100 patients across ten sites.
• Adds to PainTEQ’s portfolio alongside the existing LINQ system.

Pulse Analysis

The sacroiliac joint is a frequent source of chronic low‑back pain, and demand for minimally invasive fusion solutions has surged as insurers and physicians seek durable, cost‑effective therapies. PainTEQ, a Tampa‑based developer, entered the market with its LINQ system, which pioneered posterior SI‑joint fusion. By introducing TRAQ, the company aims to capture a broader segment of the growing $1.5 billion SI‑joint device market, offering surgeons a device that promises stronger fixation through its triangular barbs while preserving the familiar posterior approach.

TRAQ’s design differentiates it from earlier implants by targeting both sacral and iliac cortices, a feature intended to enhance stability and promote faster bony integration. The 1‑inch incision and pre‑filled graft window streamline the procedure, potentially reducing operative time and postoperative pain. Early adopters, such as Dr. Timothy Deer, highlight the device’s ease of use and the ability to expand the surgeon’s armamentarium without learning a new surgical corridor. This incremental innovation may accelerate adoption among interventionalists already comfortable with the LINQ platform.

To substantiate clinical benefits, PainTEQ launched the TRAQTION study, a prospective, multi‑center trial enrolling up to 100 patients at ten U.S. sites with 24‑month follow‑up. The study’s IRB‑approved design will generate real‑world safety and efficacy data, a critical factor for payer coverage and guideline inclusion. As the trial progresses, positive outcomes could reinforce PainTEQ’s market positioning, drive broader reimbursement, and encourage competitors to pursue similar bicortical fixation technologies, reshaping the competitive landscape of posterior SI‑joint fusion.